Opinion/decision on a Paediatric investigation plan (PIP): Takhzyro, lanadelumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Other, PIP number: P/0037/2023

P/0037/2023: EMA decision of 31 January 2023 on the refusal of a modification of an agreed paediatric investigation plan and on the granting of a product-specific waiver for lanadelumab (Takhzyro), (EMEA-001864-PIP03-19-M01)

AdoptedFirst published: 14/02/2024Reference Number: EMA/21184/2023

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

Opinion/decision on a Paediatric investigation plan (PIP): Takhzyro, lanadelumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Other, PIP number: P/0037/2023

Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.